Schülke & Mayr GmbH acquires Redditch Medical to strengthen Life Science know-how and portfolio

Norderstedt, September 23rd, 2025 – Schülke & Mayr GmbH ("schülke" or "the company") today announced the acquisition of Redditch Medical, a UK-based specialist in cleanroom contamination control solutions, including the InSpec® range of disinfectants and detergents. This strategic acquisition expands schülke’s Life Science capabilities and reinforces our commitment to seamless cleanroom decontamination for pharmaceutical and biotech customers worldwide.

Jan-Dirk Auris, CEO of schülke, commented: “Redditch Medical brings deep expertise in sterile cleanroom solutions that perfectly complements our Life Science portfolio. This acquisition is a decisive step forward in our mission to protect lives worldwide.”

The acquisition of Redditch Medical will strengthen the company’s ability to deliver tailored solutions to their customers in the pharmaceutical and biotech sectors. Redditch’s InSpec® product line and technical validation services will enhance the company’s offering in cleanroom contamination control. It will expand schülke’s footprint beyond current geographies, allowing it to serve more customers across Europe and globally.

Patric Scheidner, Head of SBU Life Science at schülke, added: “We are excited to welcome Redditch Medical to our Life Science team. Their product innovation and manufacturing excellence will enable us to accelerate our growth and better serve our customers’ evolving needs more effectively.”

Steve Brown, CEO of Redditch Medical, stated: “Joining schülke is a great opportunity for our team and our customers. We share a common vision of quality, safety, and innovation, and we look forward to contributing to schülke’s mission.”

This acquisition marks a new chapter in schülke’s Life Science strategy. With combined expertise and shared values, schülke and Redditch Medical will drive innovation in cleanroom contamination control and deliver measurable value to customers across the pharmaceutical and biotech sectors.

About Redditch Medical

Founded in 2012, Redditch Medical is a UK-based specialist in cleanroom contamination control for the Life Sciences industry. The company develops and manufactures the InSpec® range of disinfectants and detergents, designed for broad-spectrum efficacy and compliant with EN standards and Biocidal Products Regulation (BPR). All products are produced in-house under ISO 5 cleanroom conditions and in accordance with ISO 9001 and GMP principles. Redditch Medical’s validation team provides expert technical support, microbiological and chemical analytics, and tailored solutions for pharmaceutical and biotech cleanroom environments. 

For more information, visit www.redditchmedical.com.

About Schülke & Mayr GmbH (schülke)

Headquartered in Norderstedt near Hamburg, Schülke & Mayr GmbH has been a global leader in infection prevention and control for over 135 years. Infectious agents know no borders – a truth that holds even greater relevance in today’s globalized world. Committed to its mission “We protect lives worldwide”, schülke actively contributes to safety and health protection through its strategic business units: Healthcare, Over the Counter (OTC), Life Sciences, and Direct Patient Care.

With strong brands such as octenisept®, kodan®, desderman®, and microshield®, schülke is among the international market leaders in wound and mucous membrane antiseptics as well as hand and surface disinfection in German hospitals. People in more than 80 countries rely on schülke products every day.

Offering a broad portfolio of high-quality, innovative products, expert consultation, and reliable service, schülke delivers holistic solutions for infection prevention and control – across professional healthcare, consumer markets, and the pharmaceutical sector.

schülke employs more than 1,100 dedicated professionals and operates 20 subsidiaries and three production sites in Germany (schülke), France (Bioxal), and Brazil (Vic Pharma).

For more information, visit www.schuelke.com.

Kontakt

May-Britt Conradi
Head of Corporate Communications
Robert-Koch-Straße 2
22851 Norderstedt

octenisept® Vaginaltherapeutikum
Anwendungsgebiete: Antiseptikum zur Behandlung von Vaginalinfektionen. Linderung der Symptomatik bei bakteriell oder durch Pilzinfektion (Candidosen) bedingtem Juckreiz, Brennen und Ausfluss im Vaginalbereich. Warnhinweise: octenisept® Vaginaltherapeutikum nicht in größeren Mengen verschlucken oder in den Blutkreislauf gelangen lassen. Zu Risiken und Nebenwirkungen lesen Sie die Packungsbeilage und fragen Sie Ihre Ärztin, Ihren Arzt oder in Ihrer Apotheke.



Data protection notice

We use analysis methods (e.g. cookies) to measure how often our website is visited and how it is used. We also use cookies to link your page visits and website usage with your customer data stored in our CRM system in order to be able to address you individually, i.e. based on your interests and usage. We alsowe embed third-party content from other providers (e.g. videos). We have no influence on further data processing and any tracking by the third-party provider.In this context, we also use service providers in third countries outside the EU that may not guarantee an adequate level of data protection, which entails the following risks Access by authorities without informing the data subject, no data subject rights, no legal remedies, loss of control.By hiring us, you consent to the processes described above. You can revoke your consent with effect for the future. You can find more information in our privacy policy